Interleukin (IL)-33 is a cytokine of the IL-1 family, which signals through the ST2 receptor. Previous work demonstrated that the systemic administration of recombinant IL-33 reduces the development of atherosclerosis in apolipoprotein E-deficient (ApoE À/À ) mice by inducing a Th1-to-Th2 shift. The objective of our study was to examine the role of endogenous IL-33 and ST2 in atherosclerosis. ApoE
Introduction
Interleukin (IL)-33 is the most recently discovered member of the IL-1 cytokine family (see [1] for review). As a dual function protein IL-33 displays both intracellular and extracellular effects. The extracellular effect is executed by binding to its receptor T1/ST2 (ST2), a member of the IL-1 receptor family [2] . IL-33 is mainly expressed as a nuclear protein in stromal cells, including specialized fibroblasts, epithelial, and human endothelial cells, but only to a limited extent in mouse endothelial cells [3, 4] . Upon cell damage during trauma or infection, IL-33 can be released from necrotic cells and act as an alarmin to alert the immune system [3] . ST2 is predominantly expressed on type 2 innate lymphoid cells, activated Th2 lymphocytes, and mast cells [5] [6] [7] , but its expression has also been demonstrated on basophils, eosinophils, and dendritic cells. IL-33 induces the production of Th2 cytokines, enhances serum immunoglobulin synthesis and is, therefore, associated with Th2-dependent inflammatory diseases [2] .
Atherosclerosis is a chronic inflammatory disease characterized by the formation of arterial lesions, which consist of infiltrating T cells, macrophages that convert into foam cells, as well as resident smooth muscle and endothelial cells producing cytokines, growth factors, and other proinflammatory mediators [8] . Several studies provide evidence for a protective or beneficial role of IL-33 in cardiovascular biology [9, 10] . Of note, the administration of recombinant IL-33 exerted a protective effect in the apolipoprotein E-deficient (ApoE -/-) mouse model of atherosclerosis. IL-33 treatment reduced the lesion size in the aortic sinus and induced a Th1-to-Th2 switch by increasing the levels of the Th2 cytokines IL-4, IL-5, and IL-13 and decreasing the Th1 cytokine IFNg in serum and lymph node cells. Coadministration of a neutralizing anti-IL-5 antibody with IL-33 prevented the reduction in plaque size, indicating that IL-5 mediated the atheroprotective effect of IL-33. The neutralization of endogenous IL-33 by the administration of soluble ST2, which acts as a decoy receptor for IL-33, exacerbated the development of atherosclerotic plaques in the aortic sinus and led to increased IFNg levels in both serum and the supernatant of in vitro-stimulated peripheral lymph node cells [11] . These data suggested that exogenously administrated IL-33 plays a protective role in the development of atherosclerosis. However, no study addressed the development of atherosclerosis in atherosclerotic-prone mice deficient in either IL-33 or ST2. Therefore, we generated IL-33 [12, 13] . At the beginning of the cholesterol-rich diet, body weight was not different between the groups (Supporting Information  Table S1 ), but there was some variation of serum total cholesterol levels between the groups. (Supporting Information Table S2 ). After 10 weeks of cholesterol-rich diet, the body weight increased significantly, but without any significant difference between the groups (Supporting Information Table S1 ). The cholesterol-rich diet induced a significant increase of serum total cholesterol in all groups with the exception of ST2 À/À ApoE À/À mice (Supporting Information Table S2 ). The cholesterol levels after 10 weeks of diet were significantly higher in IL-33 À/À ApoEÀ/ mice than in ST2
No significant differences in the extent of atherosclerotic lesions were observed in the thoracic-abdominal aorta among all groups (Fig. 1A, C) 
, or ApoE -/-mice injected with either a blocking anti-ST2 (n ¼ 9) or the isotype control antibody (n ¼ 10) after 10 weeks of a cholesterol-rich diet.
All samples were stained with Oil Red O (red) for lipids and sections of aortic sinuses were counterstained with hematoxylin (purple). 
Expression of IL-33 in cells of the adventitia
IL-33 expression has been reported in cells expressing a-smooth muscle actin in the adventitia of atherosclerotic aortas [11] . Herein, we confirm the expression of IL-33 in the nucleus of cells in the adventitia of all groups except for IL-33 (Fig 2, upper and middle panels) .
Less IL-33-expressing cells are detected in the aortic sinus of ApoE À/À and C57BL/6 mice fed a chow diet (Fig. 2, lower panels), suggesting that IL-33 expression is either increased in resident cells in the adventitia during atherosclerosis and/ or IL-33-expressing cells are recruited to the adventitia.
The deficiency of endogenous IL-33 signaling has no impact on the Th1/Th2 cytokine profile
To determine whether the absence of IL-33 or ST2 promotes a Th1 rather than a Th2 immunological profile as described [11] , cytokine responses were assessed in in vitro cultivated sinus-draining mediastinal and peripheral 
, or ApoE À/À mice injected with either a blocking anti-ST2 or the isotype control antibody (cholesterol-rich diet) and C57BL/6 control mice (chow diet). Scale bars: 500 mm for the overview, 100 mm for the zoom. A, adventitia; M, media; I, Intima; L, lumen.
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(including axillary and inguinal) lymph node cells. Levels of IFNg were lower in the supernatant of mediastinal (Fig. 3A) , but not peripheral (Fig. 3B) [25] . However, IL-33/ST2 axis deficiency was devoid of any impact on IL-17A secretion. Taken together, the deficiency or blockage of IL-33 or ST2 did not cause major and consistent changes concerning the Th1/Th2 profile.
Concluding remarks
The results presented herein do not support a role of endogenously expressed IL-33 and ST2 in atherogenesis in ApoE-deficient mice. ) obtained from the MRC Laboratory of Molecular Biology (Cambridge, UK) [26] in order to generate IL-33
Materials and Methods

Mice
Genotyping was performed by PCR by following Jackson Laboratory protocol for ApoE À/À mice or as previously described for IL-33 À/À [18] . Genotyping for the St2 gene was 
, or ApoE -/-mice injected with either a blocking anti-ST2 (n ¼ 7-9/n ¼ 8-9) or the isotype control antibody (n ¼ 9-10/n ¼ 9-10) were stimulated with anti-CD3 and anti-CD28 for 72 h. IFNg, IL-5, and IL-17A protein levels were measured by ELISA in the supernatant. Data are shown as the mean AE SEM, 1-way ANOVA, and Tukey's post-test for pairwise comparison.
performed by a 3-primer PCR combining a common reverse primer (5'-GGAAATGCAACCAGAAGTGCACAGG-3') with forward primers specific for the wild type (5'-GCTGGATAAAGCTATATCATGG-3') or the KO (5'-GATTGCACGCAGGTTCTC-3') alleles. All mice were maintained under conventional conditions in the animal facility of the Geneva University School of Medicine, and water and food were provided ad libitum. Animal studies were approved by the Animal Ethics Committee of the Geneva Veterinarian Office (licence number: 1067/3620/1) and were performed according to the appropriate codes of practice.
Biological reagents
The monoclonal murinized IgG1 blocking anti-ST2 and the isotype matched control antibodies were generated at Amgen, Inc. Efficacy of the blocking anti-ST2 antibody was demonstrated previously [12, 13] . Cell culture media were obtained from Invitrogen Life Technologies (Basel, Switzerland). ApoE À/À mice were injected intraperitoneally twice per week for 10 weeks with PBS. Mice were weighed before and after diet. Peripheral blood was collected before and after diet. At 20 weeks of age aortas were separated into two parts, of which the thoracic-abdominal parts were fixed in 2% paraformaldehyde and the aortic sinuses were snap-frozen in OCT compound. In order to compare the data obtained in the two independent experiments, the values of the lesion areas in the thoracicabdominal aorta and the aortic sinus of not treated and PBS-injected ApoE À/À mice from the first and second experiment, respectively, were compared by unpaired twotailed Student's t-test. Since there was no significant difference, the two experiments were pooled.
Experimental design
Male ApoE
Oil Red O staining and atherosclerotic lesion analysis
The extent of atherosclerosis was assessed in thoracicabdominal aortas and aortic sinus cryosections (7 mm) with 
Serum analysis
Mouse serum total cholesterol concentrations were measured as described [27] .
Immunohistochemistry IL-33 expression was examined on frozen aortic sinus sections (7 mm). In brief, after drying at 378C, rehydration in PBS and fixation in 4% paraformaldehyde, endogenous peroxidase activity was blocked and the sections were incubated with a polyclonal goat anti-mouse IL-33 antibody (R&D Systems, Vienna, Austria; at 1 mg/mL) as described [18] and counterstained with hematoxylin. Slides were scanned with Mirax Scan (Carl Zeiss) and pictures taken using the Pannoramic Viewer software (3D HISTECH).
Culture of lymph node cells
Lymph node cells were removed and 1 Â 10 6 cells/mL were activated with plate-bound anti-mouse CD3 and anti-mouse CD28 (both 2 mg/mL; BD Pharmingen, Allschwil, Switzerland) in RPMI, 10% FCS, 50 mM b-ME, 100 U/mL penicillin, and 100 mg/mL streptomycin for 72 h.
ELISA
IFN-g, IL-5, and IL-17A protein levels in lymph node cell supernatants were determined using ELISA Ready Set Go kits (IFN-g, IL-17A) from eBioscience (Vienna, Austria) or a DuoSet ELISA kit (IL-5) from R&D Systems.
Statistical analysis
Significant variations were calculated using the unpaired or paired two-tailed Student's t-test or 1-way ANOVA with Tukey's post-test for pairwise comparison when the ANOVA was statistically significant, as indicated in the figure legends. P < 0.05 was considered significant. Results are expressed as the mean AE SEM.
SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article at the publisher's web-site. Table S1 : Body weight (g) before and after cholesterol-rich diet. Table S2 : Serum total cholesterol concentrations (mM) before and after cholesterol-rich diet.
